脂肪肉瘤认识与治疗的最新进展
Recent advances in the understanding and management of liposarcoma.
作者信息
Haddox Candace L, Riedel Richard F
机构信息
Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
Duke Cancer Institute, Durham, NC, USA.
出版信息
Fac Rev. 2021 Jan 4;10:1. doi: 10.12703/r/10-1. eCollection 2021.
Abstract
Liposarcomas are a common subfamily of soft tissue sarcoma with several subtypes recognized by the World Health Organization: atypical lipomatous tumors (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS), and myxoid pleomorphic liposarcoma (MPLPS). Despite shared adipocytic features among liposarcomas, the clinical approach to each subtype differs based on histology, location, clinical behavior, and specific oncogenic drivers. In this review, we highlight subtype-specific molecular features with the potential to generate novel therapies. We discuss recent clinical trials investigating the use of preoperative radiation therapy for retroperitoneal liposarcoma, chemotherapy, small molecule inhibitors, and innovative immunotherapy approaches and describe how we incorporate these advancements into the management of liposarcoma.
摘要
脂肪肉瘤是软组织肉瘤中常见的一个亚类，世界卫生组织认可的有几种亚型：非典型脂肪瘤性肿瘤（ALT）/高分化脂肪肉瘤（WDLPS）、去分化脂肪肉瘤（DDLPS）、黏液样脂肪肉瘤（MLPS）、多形性脂肪肉瘤（PLPS）以及黏液样多形性脂肪肉瘤（MPLPS）。尽管脂肪肉瘤之间存在共同的脂肪细胞特征，但基于组织学、位置、临床行为和特定致癌驱动因素，针对每种亚型的临床治疗方法有所不同。在本综述中，我们重点介绍具有产生新疗法潜力的亚型特异性分子特征。我们讨论了最近关于术前放疗用于腹膜后脂肪肉瘤、化疗、小分子抑制剂以及创新免疫治疗方法的临床试验，并描述了我们如何将这些进展纳入脂肪肉瘤的管理中。
相似文献
1
Recent advances in the understanding and management of liposarcoma.脂肪肉瘤认识与治疗的最新进展
Fac Rev. 2021 Jan 4;10:1. doi: 10.12703/r/10-1. eCollection 2021.
2
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.脂肪肉瘤亚型概述：遗传改变和治疗策略的最新进展。
J Mol Histol. 2024 Jun;55(3):227-240. doi: 10.1007/s10735-024-10195-4. Epub 2024 May 2.
3
Lipomatous tumors.脂肪瘤性肿瘤
Monogr Pathol. 1996;38:207-39.
4
Histology driven systemic therapy of liposarcoma-ready for prime time?组织学驱动的脂肪肉瘤全身治疗——已准备好进入黄金时代？
Transl Gastroenterol Hepatol. 2018 Nov 23;3:96. doi: 10.21037/tgh.2018.11.01. eCollection 2018.
5
Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study.黏液样多形性脂肪肉瘤通过广泛的杂合性丢失和明显更差的总体生存率与其他脂肪肉瘤区分开来：一项基因组和临床病理研究。
Mod Pathol. 2022 Nov;35(11):1644-1655. doi: 10.1038/s41379-022-01107-6. Epub 2022 Jun 7.
6
A contemporary review of myxoid adipocytic tumors.黏液样脂肪细胞性肿瘤的当代综述。
Semin Diagn Pathol. 2019 Mar;36(2):129-141. doi: 10.1053/j.semdp.2019.02.008. Epub 2019 Feb 28.
7
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.晚期脂肪肉瘤已确立的及实验性全身治疗方案
Oncol Res Treat. 2022;45(9):525-543. doi: 10.1159/000524939. Epub 2022 May 24.
8
Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.去分化脂肪肉瘤和多形性脂肪肉瘤：细针抽吸细胞学形态学和 MDM2/CDK4 表达的比较研究。
Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.
9
What's new in adipocytic neoplasia?脂肪细胞肿瘤有哪些新进展？
Virchows Arch. 2020 Jan;476(1):29-39. doi: 10.1007/s00428-019-02652-3. Epub 2019 Sep 9.
10
Differences in recurrence and survival of extremity liposarcoma subtypes.肢体脂肪肉瘤亚型的复发和生存差异。
Eur J Surg Oncol. 2018 Sep;44(9):1391-1397. doi: 10.1016/j.ejso.2018.03.028. Epub 2018 Apr 6.
引用本文的文献
1
Histomorphological and molecular characteristics of liposarcoma (Review).脂肪肉瘤的组织形态学和分子特征（综述）
Oncol Lett. 2025 Jul 21;30(4):454. doi: 10.3892/ol.2025.15200. eCollection 2025 Oct.
2
Myxoid Liposarcoma of the Thigh in Early Puerperium-Rare Case Report and Narrative Review.产褥早期大腿部黏液样脂肪肉瘤——罕见病例报告及文献综述
Diseases. 2025 Jul 14;13(7):220. doi: 10.3390/diseases13070220.
3
Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.美国转移性去分化脂肪肉瘤患者的真实世界生存结果及MDM2患病率
Future Oncol. 2025 Jun;21(14):1797-1807. doi: 10.1080/14796694.2025.2502319. Epub 2025 Jun 4.
4
Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.加拿大去分化脂肪肉瘤（DDLPS）的流行病学、治疗模式、生存率、医疗资源利用及成本：一项使用安大略省行政数据库的回顾性队列研究
Curr Oncol. 2025 May 9;32(5):273. doi: 10.3390/curroncol32050273.
5
A Rare Case of Atypical Pelvic Retroperitoneal Lipoma Mimicking Liposarcoma; A Case Report and Review of Literature.一例罕见的非典型盆腔腹膜后脂肪瘤酷似脂肪肉瘤的病例报告及文献复习
Clin Case Rep. 2025 Feb 20;13(2):e70236. doi: 10.1002/ccr3.70236. eCollection 2025 Feb.
6
Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis.黏液样脂肪肉瘤：治疗结果、转移模式及容积分析
Strahlenther Onkol. 2025 Feb 3. doi: 10.1007/s00066-025-02366-3.
7
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.靶向脂肪肉瘤：揭示分子途径与治疗机遇
Front Oncol. 2024 Dec 11;14:1484027. doi: 10.3389/fonc.2024.1484027. eCollection 2024.
8
Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report.复发性纵隔脂肪肉瘤免疫治疗效果不佳而行手术切除：1例病例报告
Future Sci OA. 2024 May 15;10(1):FSO906. doi: 10.2144/fsoa-2023-0099. eCollection 2024.
9
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.脂肪肉瘤亚型概述：遗传改变和治疗策略的最新进展。
J Mol Histol. 2024 Jun;55(3):227-240. doi: 10.1007/s10735-024-10195-4. Epub 2024 May 2.
10
Metastatic Epithelioid Pleomorphic Liposarcoma in the Brain: A Case Report.脑转移性上皮样多形性脂肪肉瘤：一例报告
Cureus. 2023 Dec 6;15(12):e50066. doi: 10.7759/cureus.50066. eCollection 2023 Dec.
本文引用的文献
1
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032).帕博利珠单抗与放疗联合对比单纯放疗用于肢体高危软组织肉瘤的随机试验（SU2C-SARC032）
Ann Surg Oncol. 2023 Feb;30(2):683-685. doi: 10.1245/s10434-022-12762-z. Epub 2022 Nov 17.
2
Phase II Study of Copanlisib in Patients With Tumors With Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.NCI-MATCH ECOG-ACRIN 试验（EAY131）子方案 Z1F：携带突变的肿瘤患者中 Copanlisib 的 II 期研究结果。
J Clin Oncol. 2022 May 10;40(14):1552-1561. doi: 10.1200/JCO.21.01648. Epub 2022 Feb 8.
3
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.黏液样脂肪肉瘤术前放疗剂量减少：一项非随机对照试验。
JAMA Oncol. 2021 Jan 1;7(1):e205865. doi: 10.1001/jamaoncol.2020.5865. Epub 2021 Jan 21.
4
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.术前放疗加手术与单纯手术治疗原发性腹膜后肉瘤患者（EORTC-62092：STRASS）：一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2020 Oct;21(10):1366-1377. doi: 10.1016/S1470-2045(20)30446-0. Epub 2020 Sep 14.
5
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.一项评估regorafenib 对比安慰剂治疗晚期/转移性、治疗后复发脂肪肉瘤的随机、双盲、安慰剂对照、II 期研究（SARC024 研究）结果。
Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20.
6
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.靶向脂肪肉瘤中的 CDK4（细胞周期蛋白依赖性激酶）扩增：全面综述。
Crit Rev Oncol Hematol. 2020 Sep;153:103029. doi: 10.1016/j.critrevonc.2020.103029. Epub 2020 Jun 18.
7
A Reappraisal of Superficial Pleomorphic Liposarcoma.浅型多形性脂肪肉瘤再评价。
Am J Clin Pathol. 2020 Aug 5;154(3):353-361. doi: 10.1093/ajcp/aqaa045.
8
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.高危软组织肉瘤的新辅助化疗：意大利（ISG）、西班牙（GEIS）、法国（FSG）和波兰（PSG）肉瘤组随机试验的最终结果。
J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18.
9
Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine.成人软组织肉瘤：在个体化医学时代，组织亚型特异性管理的最新进展。
CA Cancer J Clin. 2020 May;70(3):200-229. doi: 10.3322/caac.21605. Epub 2020 Apr 10.
10
Primary anatomical site as a prognostic factor for pleomorphic liposarcoma.原发解剖部位是多形性脂肪肉瘤的预后因素。
J Cancer Res Clin Oncol. 2020 Jun;146(6):1501-1508. doi: 10.1007/s00432-020-03204-y. Epub 2020 Apr 4.
Zotero 插件